Sector
PharmaceuticalsOpen
₹39Prev. Close
₹38.4Turnover(Lac.)
₹4.45Day's High
₹39Day's Low
₹3752 Week's High
₹5652 Week's Low
₹27.5Book Value
₹36.49Face Value
₹10Mkt Cap (₹ Cr.)
56.17P/E
23.41EPS
1.64Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 14.9 | 14.95 | 14.85 | 12.89 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 36.97 | 32.19 | 27.7 | 20.15 |
Net Worth | 51.87 | 47.14 | 42.55 | 33.04 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 55.35 | 47 | 34.12 | 28.58 |
yoy growth (%) | 17.76 | 37.72 | 19.39 | 60.68 |
Raw materials | -8.55 | -9.56 | -8.14 | -8.79 |
As % of sales | 15.45 | 20.35 | 23.86 | 30.78 |
Employee costs | -9.99 | -7.58 | -5.49 | -4.34 |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | 4.25 | 4 | 2.83 | 0.78 |
Depreciation | -5.17 | -4.63 | -3.9 | -3.35 |
Tax paid | 0.18 | -0.88 | -0.33 | 0.12 |
Working capital | 8.28 | 4.54 | 4.71 | 8.12 |
Other operating items |
Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 17.76 | 37.72 | 19.39 | 60.68 |
Op profit growth | 14.62 | 42.61 | 105.79 | 32.15 |
EBIT growth | 15.34 | 54.58 | 230.95 | 76.34 |
Net profit growth | 42.28 | 24.72 | 175.16 | 96.62 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 45.45 | 52.23 | 51.39 | 51.78 | 55.35 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 45.45 | 52.23 | 51.39 | 51.78 | 55.35 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.04 | 0.04 | 0.1 | 0.08 | 0.05 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,823.35 | 157.19 | 4,37,482.74 | 237.82 | 0.74 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,140.8 | 82.16 | 1,36,472.09 | 430 | 0.58 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,611.9 | 32.78 | 1,30,170.58 | 1,055.94 | 0.81 | 3,752.25 | 346.4 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,417 | 76.94 | 1,15,641.61 | 469 | 0.82 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,669.75 | 27.02 | 1,11,298.04 | 1,417.2 | 0.6 | 5,823.9 | 1,458.61 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Kalyan Ram Mangipudi
Whole-time Director
Alangudi Sankaranarayanan
Chairman & Independent Directo
K Sunder
Independent Director
Hariharan Ravindran
Independent Director
Kunda Kalpana
Director
Karopadi Shivanand Nayak
Whole Time Director & CFO
K Sri Kalyan
Additional Director
Shyam Sunder Tipparaju
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Vivo Bio Tech Ltd
Summary
Vivo Bio Tech Limited, established in February, 1987 is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Their experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules.The Company stands as a premier and primary provider of SPF lab animals in India. It holds the distinction of being the largest breeder and distributor of rodent models, in addition to offering custom rodent models and stem cell products through Cyagen Biosciences. The Company serves as an authorized distributor of lab animal diets from Special Diets Services (UK) in India. It pioneered the commercial distribution of SPF guinea pigs, sourcing breeders from Elm Hill Labs (USA). Employing topquality SPF breed in their in-house lab animals, the Company upholds excellence in all pre clinical studies. Their comprehensive services span a wide array of preclinical toxicology disciplines, encompassing In-vitro and In-vivo studies, analytical chemistry studies, bioanalytical studies, and physico-chemical studies. Moreover, the Company boasts supplementary satellite facilities situated in Pregnapur Village, Siddipet District, Hyderabad, Telangana. The Biologic Research Services group at Vivo B
Read More
The Vivo Bio Tech Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹37.69 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vivo Bio Tech Ltd is ₹56.17 Cr. as of 06 Sep ‘24
The PE and PB ratios of Vivo Bio Tech Ltd is 23.41 and 1.05 as of 06 Sep ‘24
The 52-week high/low is the highest and lowest price at which a Vivo Bio Tech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Vivo Bio Tech Ltd is ₹27.5 and ₹56 as of 06 Sep ‘24
Vivo Bio Tech Ltd's CAGR for 5 Years at 4.04%, 3 Years at -26.14%, 1 Year at 31.21%, 6 Month at -17.23%, 3 Month at -5.56% and 1 Month at 2.75%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice